Theranexus global offering will fund juvenile Batten disease Phase 3 trial
Theranexus has launched a global offering of around €4 million (about $4.5 million) to help fund the pivotal Phase 3 trial of the company’s investigational therapy Batten-1 for juvenile Batten disease. The Beyond Batten Disease Foundation (BBDF) acquired €1.15 million (about $1.3 million) in shares before the…